cannabidivarin cannabidivarin cannabidivarin (cbdv, gwp42006) is a non-intoxicating psychoactive cannabinoid found in cannabis. it is a homolog (chemistry) of cannabidiol (cbd), with the side-chain shortened by two methylene bridges (ch2 units). cannabidivarinclinical dataatc codenoneidentifiers iupac name 2-((1s,6s)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl)-5-propylbenzene-1,3-diol cas number24274-48-4 npubchem cid11601669drugbankdb14050 nchemspider21106275 yuniii198vbv98ikeggc20217chemblchembl2387742comptox dashboard (epa)dtxsid70893921 echa infocard100.236.933 chemical and physical dataformulac19h26o2molar mass286.415 g·mol−13d model (jsmol)interactive image smiles c=c(c)2ccc(\c)=c/2c1c(o)cc(ccc)cc1o inchi inchi=1s/c19h26o2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21h,2,5-8h2,1,3-4h3/t15-,16+/m1/s1 ykey:reozwegfphtfei-cvearbpzsa-n y ny (what is this?) (verify) although cannabidivarin (cbdv) is usually a minor constituent of the cannabinoid profile, enhanced levels of cbdv have been reported in feral populations of c. indica ( = c. sativa ssp. indica var. kafiristanica) from northwest india, and in hashish from nepal.= cbdv has anticonvulsant effects. it was identified for the first time in 1969 by vollner et al. similarly to cbd, it has seven double bond isomers and 30 stereoisomers (see: cannabidiol#isomerism). it is not scheduled by convention on psychotropic substances. it is being actively developed by gw pharmaceuticals (as gwp42006) because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action. gw has begun a phase 2 trial for adult epilepsy, and is to begin trials of this cbdv product in children in 2016 in australia.